Lilly licenses diabetes treatment from biotech firm

Eli Lilly and Co. has purchased the exclusive rights from biotech firm MacroGenics to develop teplizumab, a molecule that has potential for treating Type 1 diabetes, in a bid to further expand its diabetes drug pipeline. Teplizumab, which researchers say could protect insulin-producing beta cells of the pancreas, is currently undergoing late-stage trials to treat patients with recent-onset Type 1 diabetes.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN